The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's)

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 428-432

  Tomasson, Gunnar ^a   Davis, John C ^b   Hoffman, Gary S ^c   McCune, W Joseph ^d   Specks, Ulrich ^e   Spiera, Robert ^f   William St Clair, E ^g   Stone, John H ^h   Merkel, Peter A ^i,j  

^a UNIVERSITY OF ICELAND   (Iceland)

^b GENENTECH INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MAYO CLINIC   (United States)

^f HOSPITAL FOR SPECIAL SURGERY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j BOSTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; METHOTREXATE;

ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; EMOTION; FEMALE; HUMAN; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PAIN; PRIORITY JOURNAL; RELAPSE; REMISSION; SHORT FORM 36; SOCIAL INTERACTION; SOCIAL STATUS; VISUAL ANALOG SCALE; WEGENER GRANULOMATOSIS; COHORT ANALYSIS; COMPARATIVE STUDY; DISABILITY; EVALUATION STUDY; OUTCOME ASSESSMENT; PHYSICIAN; RECURRENT DISEASE; SELF EVALUATION; SEVERITY OF ILLNESS INDEX;

COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIANS; RECURRENCE; SELF-ASSESSMENT; SEVERITY OF ILLNESS INDEX; VISUAL ANALOG SCALE; WEGENER GRANULOMATOSIS;

EID: 84896291783     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38248     Document Type: Article

References (14)

1. Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352: 351-61.
2. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349: 36-44.
3. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363: 211-20.
4. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363: 221-32.
5. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87: 671-8.
6. Hewlett S, Sanderson T, May J, Alten R, Bingham CO III, Cross M, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count-an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012;51: 69-76.
7. Kirwan JR, Boonen A, Harrison MJ, Hewlett SE, Wells GA, Singh JA, et al. OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. J Rheumatol 2011;38: 1728-34.
8. Neogi T, Xie H, Felson DT. Relative responsiveness of physician/ assessor-derived and patient-derived core set measures in rheumatoid arthritis trials. J Rheumatol 2008;35: 757-62.
9. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44: 912-20.
10. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31: 247-63.
11. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30: 473-83.
12. Herlyn K, Hellmich B, Seo P, Merkel PA for the Vasculitis Clinical Research Consortium. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res (Hoboken) 2010;62: 1639-45.
13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38: 44-8.
14. Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al, for the Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASASendorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68: 1811-8.